Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis

To demonstrate a magnitude of the cardiovascular benefits, concomitantly analyzing the safety outcomes of sodium-glucose cotransporter 2 inhibitor (SGLT2-I) comprehensively, as a class effect in a larger sample size combined from recent randomized control trials. We searched electronic databases usi...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular endocrinology & metabolism 2021-06, Vol.10 (2), p.89-98
Main Authors: Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-akchar, Mohammad, Koester, Cameron, Ibrahim, Abdisamad, Parajuli, Priyanka, Garcia, Odalys Lara, Bhandari, Bishal, Rehman, Anis, Siddique, Momin
Format: Article
Language:English
Subjects:
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To demonstrate a magnitude of the cardiovascular benefits, concomitantly analyzing the safety outcomes of sodium-glucose cotransporter 2 inhibitor (SGLT2-I) comprehensively, as a class effect in a larger sample size combined from recent randomized control trials. We searched electronic databases using specific terms and evaluated 6 efficacy and 10 safety outcomes. Odds ratios (ORs) and 95% confidence interval (CI) were used to compare two interventions. Five studies (  = 41 267) were included, among which 23 539 received SGLT2-I. The SGLT2-I group favored reduction in major adverse cardiovascular events (OR, 0.78; 95% CI, 0.62-0.98;  = 0.03), cardiovascular death (CVD) or heart failure hospitalization (OR, 0.60; 95% CI, 0.46-0.80;  = 0.0004), rate of hospitalization for heart failure (OR, 0.56; 95% CI, 0.44-0.72;  
ISSN:2574-0954
2574-0954
DOI:10.1097/XCE.0000000000000229